Zydus Lifesciences Limited

ZYDUSLIFE

INE010B01027

Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.

Employees

26,921

Sector

Pharmaceuticals

Calendar

2025-02-13 - Q3 2025 Earnings Release

More about the company

Income Statement and Estimates

income-statement-evolution-chart ZYDUS-LIFESCIENCES-LIMITE

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

982.10INR

Average target price

1,081.28INR

Spread / Average Target

+10.10%

Consensus

Profit revisions

estimates-change-chart ZYDUS-LIFESCIENCES-LIMITE

Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart ZYDUS-LIFESCIENCES-LIMITE

Company calendar

Market Closed - NSE India S.E. Other stock markets 06:49:39 2024-12-04 am EST			5-day change	1st Jan Change
970.35 ^INR	-1.20%		+1.82%	+40.79%

Nov. 29	Zydus Lifesciences Limited Receives Demand Order-In-Original from Assistant Commissioner, Division Dehradun, Sector-7, Uttarakhand	CI
Nov. 14	Nomura Adjusts Zydus Lifesciences' Price Target to INR1,030 From INR1,020, Keeps at Neutral	MT

Zydus Lifesciences Limited Receives Demand Order-In-Original from Assistant Commissioner, Division Dehradun, Sector-7, Uttarakhand	Nov. 28	CI
Nomura Adjusts Zydus Lifesciences' Price Target to INR1,030 From INR1,020, Keeps at Neutral	Nov. 14	MT
Jefferies Adjusts Zydus Lifesciences' Price Target to INR1,380 From INR1,450, Keeps at Buy	Nov. 13	MT
Zydus Lifesciences Posts Gains in Fiscal Q2 Consolidated Net Profit	Nov. 13	MT
Zydus Lifesciences Limited, Q2 2025 Earnings Call, Nov 12, 2024	Nov. 12
India's Zydus Life posts Q2 profit rise on steady US demand	Nov. 12	RE
Zydus Lifesciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024	Nov. 12	CI
Zydus Lifesciences Limited Receives in Principle Acceptability from World Health Organization for Zyvac Tcv	Oct. 23	CI
Zydus Lifesciences Limited Receives Final Approval from USFDA for Fludrocortisone Acetate Tablets USP, 0.1 Mg	Oct. 17	CI
Zydus Lifesciences to Start Phase 2 Trials of Desidustat for Sickle Cell Disease	Oct. 14	MT
Zydus Lifesciences Limited and ICMR Initiate A Phase 2 Proof-Of-Concept Trial of Desidustat in Patients with Sickle Cell Disease	Oct. 14	CI
Zydus Lifesciences Limited Receives Final Approval from USFDA for Paliperidone Extended-Release Tablets	Oct. 10	CI
Zydus Lifesciences Gets Tentative Nod from US FDA for Enzalutamide Tablets	Oct. 02	MT
Zydus Receives Tentative Approval from USFDA for Enzalutamide Tablets, 40 Mg and 80 Mg	Oct. 02	CI
Zydus Lifesciences Limited Receives Final Approval from USFDA for Enzalutamide Capsules, 40 Mg	Sep. 28	CI
Zydus Lifesciences Limited and CSIR-Central Drug Research Institute Lucknow to Develop Best-In-Class Drug for Chronic Kidney Disease Induced Osteoporosis	Sep. 27	CI
Zydus Lifesciences to Acquire Active Pharmaceutical Ingredients Business of Sterling Biotech	Sep. 17	MT
Zydus Lifesciences Limited Receives Warning Letter from United States Food and Drug Administration	Sep. 03	CI
Zydus Lifesciences Limited Receives Demand Order-In-Original from Deputy Commissioner ST, Special Circle-VJA1: Vijayawada I: Andhra Pradesh	Aug. 30	CI
Zydus Lifesciences Limited Receives an Order-In-Original (O-I-O) of Financial Year 2019-20	Aug. 30	CI
Zydus Lifesciences Gets US FDA's Warning Letter for Injectables Plant in Gujarat, India	Aug. 30	MT
Zydus Lifesciences Limited Receives Warning Letter Issued by the USFDA	Aug. 30	CI
Zydus Lifesciences Gets US FDA Final Nod for Scopolamine Transdermal System	Aug. 30	MT
Zydus Receives Final Approval from USFDA for Scopolamine Transdermal System 1 Mg/3 Days	Aug. 30	CI
Zydus Lifesciences Arm Completes Acquisition of 50% Stake in Sterling Biotech	Aug. 30	MT

Zydus Lifesciences Limited

Equities